Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Extended-release bupropion (HCl) Clear all

Conditions: Depressive Disorder, Major, Major Depressive Disorder (MDD)
Interventions: Bupropion Hydrochloride Extended-release, Extended-release Venlafaxine; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 45
States / cities: Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more

Conditions: Cigarette Smoking-Related Carcinoma
Interventions: Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions: Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: University of Rochester NCORP Research Base; Other
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 542
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more

Conditions: Seasonal Affective Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 43
States / cities: Anchorage, Alaska • Hamden, Connecticut • Boise, Idaho + 37 more

Conditions: Depressive Disorder
Interventions: Bupropion HCl; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 25 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 2
States / cities: Culver City, California • Glendale, California

Conditions: Major Depressive Disorder (MDD)
Interventions: Extended-Release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 23
States / cities: Berkeley, California • Beverly Hills, California • La Mesa, California + 20 more

Conditions: Obesity
Interventions: Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Obesity
Interventions: Not listed
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 31,889 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Brentwood, Tennessee

Conditions: Obesity
Interventions: Naltrexone-Bupropion (NB) Combination, Placebo; Drug
Lead sponsor: Currax Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 8,600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 140
States / cities: Birmingham, Alabama • Cullman, Alabama • Mobile, Alabama + 111 more

Conditions: Obesity, Cardiovascular Diseases
Interventions: Naltrexone HCl/Bupropion HCl ER, Placebo; Drug
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 139
States / cities: Alexander City, Alabama • Auburn, Alabama • Birmingham, Alabama + 136 more

Conditions: Major Depressive Disorder (MDD)
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 24
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Berkeley, California + 19 more

Conditions: Lung Non-Small Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Nicotine Replacement, Bupropion Hydrochloride Controlled-release, Varenicline, Tobacco Cessation Counseling, Questionnaire Administration, Quality of Life Assessment, Best Practice; Drug · Other
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Heart Repolarization
Interventions: Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin; Drug · Other
Lead sponsor: Orexigen Therapeutics, Inc; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone Hydrochloride, Bupropion HCl Extended Release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions: Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy; Drug · Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Obesity
Interventions: Semaglutide, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion, Liraglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Weight Regain Post Bariatric Surgery
Interventions: Naltrexone HCl/Bupropion HCl Placebo, Naltrexone HCl/Bupropion HCl; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Chicago, Illinois • Boston, Massachusetts

Conditions: Epilepsy, Major Depressive Disorder (MDD)
Interventions: Extended-release bupropion (HCl); Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2005
U.S. locations: 24
States / cities: Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more

Conditions: Depressive Disorder
Interventions: Extended-release Bupropion Hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 48
States / cities: Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more

Conditions: Drug Drug Interaction
Interventions: EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion; Drug
Lead sponsor: Epygenix; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: End Stage Renal Disease, Fatigue
Interventions: Bupropion Hydrochloride 150 MG; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 25 Years to 74 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Stimulant Use, Relapse, Cognitive Function, ADHD
Interventions: Contrave 8Mg-90Mg Extended-Release Tablet, Bupropion; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Attention Deficit Disorder
Interventions: Extended-release bupropion hydrochloride; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 21
States / cities: Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more

Conditions: Depression
Interventions: generic bupropion; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 25 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Sexual Functioning Study With Antidepressants

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

Prevention of Seasonal Affective Disorder

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

Effects of Antidepressants on Sexual Functioning

Individualized Obesity Pharmacotherapy

Real-World Evidence on the Cardiovascular Safety of CONTRAVE® in the United States (U.S.)

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

Naltrexone/Bupropion Cardiovascular Outcomes Study

Effects Of Antidepressants On Sexual Functioning In Adults

Effectiveness of an Enhanced Tobacco Intervention Protocol Compared to Standard Treatment in Helping Head and Neck and Lung Cancer Patients Starting Treatment to Reduce Cigarette Use

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America

Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery

Lethargic Depression Study

Seasonal Affective Depression (SAD) Study

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

Relapse Prevention in Stimulant Use Disorder

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns